Abstract
REPORT HIGHLIGHTS
- The global nanomedicine market reached $63.8 billion in 2010 and $72.8
billion in 2011. The market is expected to grow to $130.9 billion by 2016 at a
compound annual growth rate (CAGR) of 12.5% between years 2011 and 2016.
- The central nervous system (CNS) products market reached $11.7 billion in
2010 and $14.0 billion in 2011. It is expected to grow to $29.5 billion by
2016, a CAGR of 16.1% between years 2011 and 2016.
- The anticancer products market reached $25.2 billion in 2010 and $28.0
billion in 2011. It is expected to reach $46.7 billion by 2016, a CAGR of
10.8% between years 2011 and 2016.
SUMMARY FIGURE
NANOMEDICAL GLOBAL SALES BY THERAPEUTIC AREA, 2009-2016
($ BILLIONS)
Source: BCC Research
STUDY GOALS AND OBJECTIVES
The aim of this report is to provide detailed market, technology and industry
analyses to help readers quantify and qualify the market for prescription drug
products incorporating nanotechnology features. Important trends are
identified and sales forecasts by product categories and major country markets
are provided through 2016; these are based on industry sources and considered
assessment of the regulatory environment, healthcare policies, demographics,
and other factors that directly affect the nanomedicine-related drug market.
The wider economic environment is also taken into account.
The report examines strategies employed by companies specializing in
nanomedicine to meet the challenges of this highly competitive market.
REASONS FOR DOING THE STUDY
Nanomedicine is already an established market. Unlike some other potential
applications of nanotechnology, which are still largely experimental,
nanomedicine has already produced a number of significant products in which
the nano dimension has made a significant contribution to product
effectiveness. Now that aspects of the nanomedicine market are established, it
is appropriate to review the technology, see its practical applications so
far, evaluate the participating companies and look to its future.
SCOPE OF REPORT
This report discusses the implications of technology and commercial trends in
the context of the current size and growth of the pharmaceutical market, both
in global terms and analyzed by the most important national markets. The
important technologies supporting nanomedicine are reviewed, and the nature
and structure of the nanomedicine industry is discussed with profiles of the
leading 60+ companies, including recent M&A activity. Five-year sales
forecasts are provided for the national markets and the major therapeutic
categories of products involved.
MARKET ANALYSES AND FORECASTS
Market figures are based on revenues at the manufacturer level and are
projected at 2011-dollar value without attempting to predict the effect of
inflation/deflation.
Therapeutic categories quantified and forecast include cancer, CNS diseases,
infections and cardiovascular. Country markets analyzed are the U.S., Japan,
Germany, France, UK, Italy, and Spain.
METHODOLOGY
Primary research includes interviews with leading individuals in nanomedicine
companies and industry associations. Primary sources of published data include
company annual reports, SEC filings, and government and industry publications.
Secondary sources consist of literature searches, industry journals and other
commercial publications. Data for market estimates and forecasts are pooled
from a range of sources, critically assessed by BCC.
INFORMATION SOURCES
Sources of information included marketing strategists, industry executives,
government agencies and regulatory bodies, and surveys of physicians and
pharmacists. Company annual reports and SEC filings, journal articles, and
data from healthcare institutions were also mined, as well as publications of
relevant trade associations.
ANALYST CREDENTIALS
Paul Evers has been involved in analyzing pharmaceutical and medical
markets for 20 years. He is the author of previous reports on the nanomedicine
marketplace as well as analyses of major therapeutic categories and the
pharmaceutical regulatory environment.
Table of Contents
Nanotechnology in Medical Applications: The Global Market
Chapter - 1: INTRODUCTION - Complimentary
- STUDY GOALS AND OBJECTIVES
- REASONS FOR DOING THE STUDY
- SCOPE OF REPORT
- MARKET ANALYSES AND FORECASTS
- METHODOLOGY
- INTENDED AUDIENCE
- INFORMATION SOURCES
- ANALYST CREDENTIALS
- RELATED BCC REPORTS
- BCC ON-LINE SERVICES
- DISCLAIMER
Chapter - 2: SUMMARY
- DEFINITION
- RESEARCH AND COMMERCIALIZATION
- APPLICATIONS
- MARKET
- Table Summary :
- Figure Summary : NANOMEDICAL GLOBAL SALES BY THERAPEUTIC AREA, 2009-2016
Chapter - 3: OVERVIEW
- MEDICAL NANOTECHNOLOGY: NANOMEDICINE
- FUTURE POSSIBILITIES
- MARKET POTENTIAL
- ABOUT NANOTECHNOLOGY
- THE MANY USES OF NANOTECHNOLOGY
- THE TOOLS OF NANOTECHNOLOGY
- RISKS OF NANOTECHNOLOGY
- NANOTECHNOLOGY IN THE MARKETPLACE
Chapter - 4: NANOMEDICINE
- DEVELOPMENT OF NANOMEDICAL TECHNOLOGIES
- THERAPEUTIC USES OF NANOMEDICINE
- THE RISK FACTOR
Chapter - 5: MARKETS FOR NANOMEDICINE
- MARKET DRIVERS
- MARKET ESTIMATES AND FORECASTS
- GLOBAL NANOMEDICINE MARKET
- MAIN PRODUCT CATEGORIES
Chapter - 6: THE NANOMEDICINE INDUSTRY
- ABLYNX
- ABRAXIS BIOSCIENCE
- ACCESS
- ACRYMED INC.
- ACUSPHERE
- ADVANCED MAGNETICS
- ALLTRACELL
- ALPHARX INC.
- ANSON NANO-BIOTECHNOLOGY (ZHUHAI) CO., LTD.
- APHIOS CORP.
- BIOCRYSTAL LTD.
- BIOFORCE NANOSCIENCES
- BIO-GATE
- BIOPHAGE PHARMA
- BIOPHAN TECHNOLOGIES
- BIOSANTE PHARMACEUTICALS INC.
- CALANDO PHARMACEUTICALS
- CAMURUS AB
- CAPSULUTION PHARMA AG
- COMBIMATRIX CORPORATION
- DAMAGE PREVENTION CONCEPT
- ELAN DRUG TECHNOLOGIES
- ENZON PHARMACEUTICALS, INC.
- FARFIELD SCIENTIFIC
- GE HEALTHCARE LIFE SCIENCES
- GILEAD
- HEALTHPLUS INTERNATIONAL INC.
- IGI INC.
- JR NANOTECH, PLC
- KEREOS, INC.
- KEYSTONE NANO, INC.
- KLEINDIEK NANOTECHNIK GMBH
- LABOPHARM INC.
- LIPLASOME PHARMA A/S
- LUMERA CORPORATION
- MAGFORCE NANOTECHNOLOGIES AG
- MAGNAMEDICS GMBH
- MICROFLUIDICS INTERNATIONAL CORPORATION
- MIV THERAPEUTICS INC.
- MOLECULAR PROFILES
- NANOBIO CORPORATION
- NANOBIOTIX
- NANOCARRIER CO., LTD.
- NANOCYTE INC.
- NANOGEN INC.
- NANOINK, INC.
- NANOLOGIX, INC.
- NANOMED PHARMACEUTICALS, INC.
- NANL-MIX INC.
- NANOPHARM AG
- NANOSPECTRA BIOSCIENCES, INC.
- NANOSPHERE, INC.
- NANOSTRUCTURES, INC.
- NANOSYN INC
- NANOTHERAPEUTICS, INC.
- NANOTROPE INC.
- NANOVIRICIDES INC.
- NUCRYST PHARMACEUTICALS
- NUTRALEASE
- ORTHOVITA INC.
- PIONEER SURGICAL TECHNOLOGY
- PSIVIDA LTD.
- QIAGEN N.V.
- SKYEPHARMA PLC
- SOLUBEST
- STARPHARMA HOLDINGS LTD.
- TECAN GROUP LTD.
- TELOMOLECULAR CORPORATION
Chapter - 7: APPENDIX
List of Tables
- Summary Table : NANOMEDICAL GLOBAL SALES BY THERAPEUTIC AREA, THROUGH 2016
- Table 1 : NANOMEDICINE TIMESCALE
- Table 2 : MAIN NANOTECHNOLOGIES USED IN MEDICINE, WITH APPLICATIONS
- Table 3 : MARKETED LIPOSOME NANOPHARMACEUTICALS
- Table 4 : NANOCRYSTAL PHARMACEUTICALS
- Table 5 : MARKETED AND DEVELOPMENTAL PRODUCTS IN MICELLE FORM
- Table 6 : MARKETED PRODUCTS WITH NANO-ENHANCED DELIVERY
- Table 7 : EUROPEAN NANOCENTRES
- Table 8 : MARKETED NANOPHARMACEUTICALS
- Table 9 : MARKETED NANO-IMAGING, DIAGNOSTICS, BIOMATERIALS
- Table 10 : SHARE OF NANOTECHNOLOGY REVENUES BY INDUSTRY SECTOR, 2010
- Table 11 : GLOBAL NANOMEDICINE MARKET, THROUGH 2016
- Table 12 : MAJOR MARKETED ANTICANCER NANOPHARMACEUTICALS, 2010
- Table 13 : MARKET FORECAST FOR CANCER NANOTHERAPEUTICS AND
NANODIAGNOSTICS, THROUGH 2016
- Table 14 : MAJOR MARKETED CNS NANOPHARMACEUTICALS, 2010
- Table 15 : MARKET FORECAST FOR CNS NANOMEDICINES, THROUGH 2016
- Table 16 : MAJOR MARKETED ANTI-INFECTIVE NANOPHARMACEUTICALS, 2010
- Table 17 : MARKET FORECAST FOR ANTI-INFECTION NANOTHERAPEUTICS AND
NANODIAGNOSTICS, THROUGH 2016
- Table 18 : MAJOR MARKETED NANOMEDICINES FOR CARDIOVASCULAR AND
AUTO-INFLAMMATORY DISEASES, 2010
- Table 19 : MARKETS FOR CARDIOVASCULAR AND ANTI-INFLAMMATORY NANOPRODUCTS,
THROUGH 2016
- Table 20 : U.S. NANOMEDICINE MARKET, THROUGH 2016
- Table 21 : NANOMEDICINE MARKET IN JAPAN, THROUGH 2016
- Table 22 : NANOMEDICINE MARKET IN GERMANY, THROUGH 2016
- Table 23 : NANOMEDICINE MARKET IN FRANCE, THROUGH 2016
- Table 24 : NANOMEDICINE MARKET IN UNITED KINGDOM, THROUGH 2016
- Table 25 : NANOMEDICINE MARKET IN ITALY, THROUGH 2016
- Table 26 : NANOMEDICINE MARKET IN SPAIN, THROUGH 2016
- Table 27 : GLOSSARY
List of Figures
- Summary Figure : NANOMEDICAL GLOBAL SALES BY THERAPEUTIC AREA, 2009-2016
2016年全球奈米醫療市場將達到1,309億美元規模
2012年02月13日
Global Information, Inc.已開始銷售BCC Research所發行的報告書「Nanotechnology in Medical Applications: The Global Market (醫療應用領域的奈米科技全球市場)」
依據本報告書的預測，2011年全球的奈米醫學(奈米醫療)市場之銷售額是728億美元，之後以複合年成長率(CAGR)12.5％成長，2016年時達到1,309億美元。
依據治療應用，利用於醫藥的奈米技術市場可分成6個部門。亦即心血管藥、抗炎症劑、抗感染症藥、中樞神經系(CNS)用藥、抗癌劑、以及其他應用的部門。
2011年心血管藥部門是40億美元規模，預計之後以CAGR 16.5％成長，2016年時達到86億美元。
2011年抗炎症劑部門是73億美元規模，預計之後以CAGR 15.2％成長，2016年時變成148億美元。
2011年抗感染症藥部門是93億美元規模，預計之後以CAGR 9.7％成長，2016年時達到148億美元。
2011年中樞神經系(CNS)用藥部門是140億美元規模，預計之後以CAGR 16.1％成長，2016年時變成295億美元。
抗癌劑部門變成最大部門，2011年是280億美元規模，預料之後以CAGR 10.8％成長，2016年時變成467億美元。
最後是其他應用部門，2011年是102億美元規模，預計之後以CAGR 10.1％成長，2016年時達到165億美元。
